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ABSTRACT 
Background  
Dressing of donor sites in split-thickness skin grafts can be traumatic for the patient.  The 
associated pain and discomfort has impelled a myriad of publications in the quest for the 
ultimate dressing.  The most advanced and expensive dressings have been studied and 
compared to the most basic of dressings, with little or no consensus and an unpersuasive 
level of evidence. 
Objectives 
We aimed to determine the efficacy of the locally manufactured non-adherent, 
hydroconductive Drawtex® dressing and compare it to the standard-of-care dressing in our 
setting, Opsite®, in the healing of split-thickness donor sites. 
Methods 
In this prospective, within-patient controlled and multi-center study, we included 27 adult 
participants, each with two split-thickness skin graft donor sites: one donor site wound was 
dressed with Drawtex® and the other one with Opsite®.  The 54 donor site wounds were 
compared with regard to time to re-epithelialisation, perceived pain of the patient and 
quality of the healed wound.   
Results 
Comparing Drawtex®- and Opsite® dressings in the healing (defined as >90% of 
epithelialised surface) of donor site wounds, 22.2% of Drawtex® and 3.7% of Opsite® 
wounds were healed by day 5 (p=0.00002).  On day ten and fifteen; 88.9% vs 85.2% and 
100% vs 96.2%, of donor site wounds were healed for Drawtex® and Opsite® respectively.  
The hydroconductive dressing treated donor site wounds were significantly less painful than 
the Opsite®-treated donor sites wounds at 24-hours, 48-hours and 7-days post-operatively.  
Overall, there were less complications in the hydroconductive dressing group and the wound 
healing quality was superior to that of the Opsite®-treated group. 
Conclusion 
Drawtex® is a relatively cheap and readily available dressing made locally in South Africa. 
In this study we have demonstrated Drawtex® to be at least as safe, and potentially superior 
in wound healing, when compared to our current standard-of-care dressing, Opsite®. 
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CHAPTER 1 
INTRODUCTION  
 
 Background 1.1
Split-thickness skin graft (STSG) donor sites are partial-thickness wounds that heal by the 
process of epithelialisation.  These wounds are painful and run the risk of infection, 
conversion to full-thickness wounds, and scar hypertrophy.  Many therapies have been 
introduced for the treatment of a STSG donor site wound (DSW).  The ideal dressing should 
be one that maintains a moist pH-balanced wound, manages exudates, limits infections, 
minimizes disturbance of the healing tissue beneath the dressing, reduces pain to the patient, 
and limits the number of dressing changes.  
 
There is extensive literature available on the dressings and management of STSG DSWs. A 
wide variety of dressings, ranging from simple dressings, such as transparent polyurethane 
film, to more complex dressings like silver (Acticoat®)
[1]
 or growth-factor impregnated 
dressings (rh-aFGF)
[2] 
have been studied in the management of STSG DSWs, with lack of 
consensus from these studies.  In a review article of 33 studies in 1998, the available 
empirical evidence regarding STSG donor site dressings was integrated and the authors 
concluded that transparent polyurethane film was the best dressing of care with the fastest 
healing rates, a smooth re-epithelialised surface and a low infection rate, in addition to the 
least amount of pain experienced and at a minimal cost.
[3]
  It is known however, that 
disadvantages to the transparent polyurethane film dressing includes post-operative leakage 
from under the dressing of the DSW, as well as fragility of this newly healed donor site.
[4]
  
More recently, a single-centre randomised control trial again showed superior results with a 
transparent, breathable film, i.e. Mepitel film®, compared to more modern dressings.
[5] 
 
 
In contrast, some studies have shown that other dressings perform better than transparent 
polyurethane film: Bovine collagen in a comparison cohort study proved to achieve greater 
epithelialisation and less pain with dressing changes compared to a transparent polyurethane 
film
[6]
, but at much greater cost.  Most studies compare dressings to one another based on, 
but not limited to, the following criteria: days to epitheliazation, VAS pain scores and 
wound quality, factoring in the incidence of complications and cost effectiveness.   
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Regarding epithelialisation, it is evident from the literature that the healing of DSWs occurs 
on average on day 10 with a range of nine to 21 days.
[1, 5, 7-14] 
This average however, was 
slightly earlier at 7.9 days for a Hydrofiber dressing.
[15]
   
In a study in 2009, 100 consecutive patients’ DSWs were dressed with a range of dressings 
including Aquacel Ag®, Bactigras®, Comfeel®, Adaptic® and Opsite®. Where none of the 
dressings were reported to be ideal, the Opsite® dressing showed a mean  (SD) VAS pain 
scale score of 2.8 (2.2), 2.1 (1.4) and 1.6 (1.2) on days four, seven and 14, respectively. 
Alhough VAS scores were low, it was the second most painful dressing, but nevertheless 
one of the most cost-effective.
[12]
  In another study by Lauchli’s group, basic transparent 
polyurethane film was contrastingly shown to be significantly less painful than other highly 
absorbtive, modern dressings, like Calcium Alginate.
[16] 
 
Complications are key factors in assessing quality of the final epithelialized DSW. From the 
literature, the ionic silver containing hydrofiber dressing, when compared to paraffin gauze, 
was also found to be superior in guarding against secondary infection
[15]
, again these 
dressings are expensive and not readily available within the state sector South African 
hospitals. 
 
At our institution the current standard of care dressing for STSG DSWs is  Opsite® (Smith 
& Nephew (Pty) Ltd, Pinetown, KZN, South Africa), a transparent polyurethane film which 
is adherent to the wound surface and is re-inforced by a crepe bandage.  The frequency with 
which the dressings are changed is arbitrary and dictated by the volume of drainage or the 
physical condition of the dressing.   Drawtex® (Beier Drawtex Healthcare (Pty) Ltd. 
Pinetown, KZN, South Africa), is a hydroconductive, non-adherent functional dressing 
which is locally manufactured by a South African company and is readily available in our 
state sector hospitals. It is a non-complex and relatively cheap dressing, at R29.18 ($2.46) 
for a 100x100 mm sheet (personal correspondence with Drawtex South Africa on 31
st
 
January 2018). It utilises Levafibre technology involving a combination of two types of 
cross-action structures that create the ability to move exudate from the wound bed through 
the dressing, reducing the amount of deleterious bacteria, cytokines and harmful matrix 
metalloproteases 
[17-18]
.   
To date, this hydroconductive dressing have not been compared in a prospective study to the 
current standard of care: thin transparent polyurethane film dressing, Opsite®.  
Consequently, the question of whether the use of this hydroconductive dressing is superior 
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in the healing of STSG DSWs in our setting when compared to thin film remains 
unanswered. We therefore aimed to investigate the efficacy of this hydroconductive dressing 
compared to thin film in the healing of STSG DSWs, specifically pertaining to healing time, 
quality of healing, pain and infection rates.  
 
 
 Objectives 1.2
We aimed to investigate the efficacy of the non-adherent hydroconductive dressing, 
compared to thin film, the current standard dressing of care, in the healing of STSG DSWs: 
The primary objectives of the study were: 
1. To compare the length of time to complete healing (i.e. >90% re-
epithelialisation). 
2. To determine the quality of healing at the time of dressing changes and then at 
three months, as determined by presence of scar hypertrophy, pruritus, 
erythema and/or induration. 
 
The secondary objectives of the study were: 
1. To measure the patients’ pain experienced using the Visual Analog Score 
(VAS) for Pain at 24-hours, 48-hours and 7-days post application. 
2.  To determine and compare the safety of the dressings with regard to the 
presence of infection and the conversion of the DSW to a full-thickness wound.  
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CHAPTER 2 
METHODS 
 Study design, setting and participants 2.1
This was a prospective, within-patient controlled and multi-center study that compared two 
wound dressings for the treatment of adult STSG DSWs. Study participants were recruited 
from two public hospitals in Johannesburg, South Africa: the Chris Hani Baragwanath 
Academic Hospital (CHBAH) situated in Soweto, which serves a lower-income population 
of approximately 2.5 million people, and the Helen Joseph Hospital (HJH) situated in 
Westdene, which serves a mixed socio-economic population of about 200 000 people. 
Eligible study participants were adult patients ≥18 years old who presented either to the 
Burns Unit at CHBAH or to the General Surgery unit at HJH and who required a STSG with 
two resultant non-contiguous DSWs. 
Patients were excluded if they 
1. Had any co-morbidities that are known to impede wound healing, such as 
HIV/AIDS, cancer or uncontrolled Diabetes Mellitus. 
2. Were pregnant, or 
3. Were on immune-suppresive- or systemic corticosteroid therapy. 
 
 
 Allocation of DSW dressings and standard surgical technique 2.2
Two non-contiguous DSWs of 50-250 cm
2
 were created by the study’s two investigative 
surgeons. The total area of the DSWs did not exceed the size of defect that needed to be 
covered. DSW depth was 0.23-0.30 mm (0.010-0.012 inches).  Both DSWs on a single 
patient were harvested to the same depth. 
Allocation of DSW dressings were done at random, using a pre-determined random 
assignment of treatments to the two defined wound regions A and B. The randomisation 
scheme was designed using a computer-generated list (MS Excel). Initially the paired DSW 
regions would be labeled A and B by the surgeon, after which an envelope was opened that 
indicated which treatment to assign to region A and which to region B. Thus, one DSW 
would randomly receive the hydroconductive dressing whilst the other DSW received the 
thin film dressing. 
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The hydroconductive dressing was applied over and above a single layer of paraffin gauze 
that covered the wound surface. The thin film dressing was applied immediately adjacent to 
the wound surface. Crepe bandage was used to re-enforce both dressings and blind the 
patient to the dressings. The latter could be replaced as needed, whilst the hydroconductive 
dressing or thin film layer would remain in place.  If the inner layer of the hydroconductive 
dressing or thin film dressing had to be removed and replaced, it was to be noted as such in 
the research record.  
 
If the clinician suspected infection at the donor site, based on clinical acumen, the dressing 
would be removed (and replaced with ‘like’ dressing material), a broad-spectrum anti-
microbial commenced and a pus swab was taken to facilitate goal directed treatment for the 
specific organism.    
 
 
 Data collection 2.3
Data, including VAS pain scores, was collected at baseline, 24-hours, 48-hours and at 7-
days after application of the study dressings.  Final data was collected at three months. On 
post-operative days 5, 10 and 15, photographs of the DSWs were taken denoting the time to 
healing, i.e. >90% re-epithelialisation. To assess the pain intensity experienced on the days 
of data collection, investigators recorded the patients’ VAS score for each donor site. The 
VAS score is a pain scale ranging from ‘no pain’ (score of 0) to ‘unbearable pain’ (score of 
10).  
If the patient became an outpatient, he or she would return to the outpatient clinic to be 
reassessed for wound healing.  The surgeon would remove and replace the covering wound 
dressing if he felt that it was surgically indicated to do so. Again, such cases were noted as 
an adverse event. 
 
 
 Ethical approval 2.4
The study protocol was approved by the Human Research Ethics Committee (Medical) of 
the University of the Witwatersrand, South Africa (clearance certificate no. M130105). 
Signed informed consent was obtained, with an interpreter present, from all study 
participants prior to enrolment into the study. 
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 Statistical analyses 2.5
The STATISTICA suit of analysis software, Version 12.7 (Statsoft Inc., Oklahoma USA) 
was used for all statistical analyses. Descriptive statistics was performed for each variable. 
Statistical analyses to compare the hydroconductive dressing- to the thin film-treatment 
groups were carried out with the following tests: 
- Wilcoxon matched pairs test for treatment comparisons on continuous and ordinal 
variables. 
- McNemar Chi-square test for within-subject testing of equality of proportions. 
A p-value of <0.05 was considered significant.   
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CHAPTER 3 
 
RESULTS 
Between March 2015 and July 2016, 38 participants were identified that met the inclusion 
criteria of our study and gave written informed consent to participate. A total of 11 patients 
were excluded because of early loss to follow-up. Of the 27 participants included in the 
study, 20 had full data sets. The mean (SD) age was 34.8 (10.9) years, with the distribution 
showing a slight imbalance to the younger population group. The age range was 18-61 years 
with a female (n=7) to male (n=20) ratio of 1:2.86. Even though the mean (SD) age of the 
males at 33.8 (9.7) years were slightly younger than the females at 37.6 (14.4) years, this did 
not reach statistical significance (Figure 3.1). 
 
 
 
 
Figure 3.1. Box & Whisker plot of the study population age according to gender.  
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Efficacy assessment 
Epithelialisation 
Complete epithelialisation was defined as the day when >90% of the DSW surface had re-
epithelialized. As seen in Figure 3.2, the percentage of patients with re-epithelialized DSWs 
was compared between the hydroconductive dressing and the thin film-treated groups on 
Day-5, -10 and -15. Almost a quarter (22.2%, n=6) of DSWs in the hydroconductive 
dressing group had epithelialized by Day-5, compared to only 3.7% (n=1) in the thin film 
group. This difference reached statistical significance with the McNemar Chi-square test, a 
within-subject test of equality of proportions (P=0.00002). Interestingly, the paired 
hydroconductive dressing donor site corresponding to this one epithelialized thin film donor 
site at Day-5 had not yet epithelialized. At Day-10, 88.9% of donor sites treated in the 
hydroconductive dressing group were epithelialized compared to 85.2% in the thin film 
group (McNemar Chi-square test, P<0.0001). Noteworthy yet again, the remaining three 
hydroconductive dressing donor sites that had not yet epithelialized by Day-10, had already 
epithelialized in the corresponding paired thin film donor sites within these participants. By 
Day-15, all DSWs in the hydroconductive dressing group had epithelialized and one 
patient’s thin film DSW had not yet epithelialized.  
 
 
 
Figure 3.2. Day of epithelialisation of donor site wound dressing Drawtex® vs Opsite® 
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Pain 
The VAS pain scale was applied to measure pain intensity at the donor sites at 24-hours, 48-
hours and 7-days post-operatively. Table 3.1 shows a comparison of the frequencies of the 
pain scores between the hydroconductive dressing and thin film-treated donor sites.  
 
 
Table 3.1. Mean VAS for Pain intensity at donor sites 
Time Drawtex® 
Mean (SD) 
Opsite® 
Mean (SD) 
P-value
*
 
24-hours 3.33 (1.92) 3.93 (2.59) 0.044 
48-hours 2.44 (1.87) 3.03 (2.19) 0.052 
7-days 1.19 (1.11) 2.04 (1.72) 0.015 
* 
Wilcoxon matched pairs test 
 
 
Safety assessment 
The quality of healing of the DSWs was continuously assessed at dressing changes and at 
the time of final evaluation at three months.  This was done by determining the presence or 
absence of the following adverse events: induration, pruritus, erythema and scar 
hypertrophy. Where 66.7% (n=18) of patients reported the presence of an adverse event in 
the thin film-treated DSW, only 25.9% (n=7) of patients reported an adverse event in the 
hydroconductive dressing group. From the bivariate distribution of the presence of adverse 
events for the two dressings shown in Figure 3.3, it is evident that for most of the 
participants (n=11, 61.1%) with an adverse event in the thin film-treated donor site, no 
events are present in the hydroconductive dressing treated donor site. This finding reached 
statistical significance with a P-value of 0.003. Furthermore, if an adverse event was present 
in the hydroconductive dressing treated donor site (n=7), an adverse event was also present 
in the thin film-treated donor site. The frequency results for specific adverse events are 
displayed in Table 3.2 and Figure 3.4.  
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Figure 3.3. Bivariate distribution of all adverse events in the Drawtex® and Opsite® 
donor sites.  
‘0’, no event; ‘1’, event present. 
 
 
 
Table 3.2. Frequency and day of adverse events   
 Drawtex® Opsite® 
Adverse event Frequency Day noted Frequency Day noted 
Induration 3.7% 10 7.4% 12.5 
Pruritus 7.4% 10 25.9% 7.1 
Erythema 7.4% 17.7 33.33% 7.2 
Scar hypertrophy 18.5% 90 40.75% 90 
 
 
 
N=11 
N=7 
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Figure 3.4. Frequency of adverse events noted in the Drawtex® and Opsite® donor 
sites.  
 
With regard to infections, two patients had an infection, one in each of the hydroconductive 
dressing and thin film groups on day 15 and 5, respectively. Finally, only one DSW resulted 
in a full-thickness conversion and was from the thin film-treated group. 
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CHAPTER 4 
DISCUSSION  
We know from the literature that the dressing of DSWs, which in the case of a STSG 
includes the epidermis and varying amounts of dermis, is fraught with complications. In 
addition, it is often is a traumatic experience for the patient and may tax healthcare 
resources.
[19]
   
The aim of dressing the DSW is to enhance healing and to reduce the pain and discomfort 
experienced in the patient while the dressing is in place.
[19]
  This should be achieved with as 
few as possible dressing changes, the latter of which reduces the risk of pulling migrating 
epidermal cells from the wound surface.
[20]
  The quest for the panacea of all dressings is 
reflected in the diversity and number of publications in this regard.  The most complex and 
expensive of dressings, as mentioned earlier, including Biobrane®
[20]
, lipid-colloids
[9]
 and 
even oxygen diffusion dressings
[10]
 have been employed.  Decreased infection rates
[15]
 and 
exudation
[20] 
have been shown from these studies, but the levels of evidence are insufficient 
to suggest a change in policy. 
Recently, novel concepts like an autologous skin cell suspension has shown accelerated 
healing rates in DSWs
[7]
, but fails to compare this to more conventional and readily 
available dressing approaches. Moreover, cost is a determining and mitigating factor, 
especially in the South African State Care setting: a resource constrained environment. 
 
In this study we challenged the above mentioned complications of the transparent 
polyurethane film dressings i.e. leakage, pain and fragile epithelilisation
[4]
 by assessing the 
efficacy of the hydroconductive dressing in a within-patient controlled model. The latter 
model excluded the potential bias that local- and systemic conditions, age and gender could 
have on the process of wound healing. We photographed both within-patient DSWs at Day-
5, -10 and -15 to assess for >90% epithelialisation. By Day-5, our study achieved 
significantly quicker rates of epithelialisation with the hydroconductive dressing when 
compared to thin film with 22% and 3.7% fully epithelialized, respectively (P=0.00002). 
Furthermore, on Day-15 all hydroconductive dressing wounds were epithelialized compared 
to 96.3% of thin film wounds.  Again from the literature, the average day of epithelialisation 
for thin film is on day 10 with a range of nine to 21 days.
[1, 5, 7-14]
  In our hydroconductive 
dressing and thin film-treated groups, 88.9% and 85.2% of DSWs had fully re-epithelialised 
by day 10. 
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When assessing the pain experienced at the DSWs in our study population, the 
hydroconductive dressing had a mean VAS score of 3.33 at 24 hours compared to 3.93 for 
thin film (P=0.044). This difference was even more significant by Day-7 (P=0.015) with 
mean VAS scores of 1.19 and 2.04 for the hydroconductive dressing and thin film groups, 
respectively. Our pain scores for thin film was in keeping with the literature that showed a 
mean VAS score for thin film on Day-7 of 2.1
[12]
. Furthermore, our hydroconductive 
dressing’s pain scores were much lower compared to those reported in the literature for 
another hydrofiber dressing, i.e. with a mean VAS score of 3.12 on Day 7.
[15] 
  
The hydroconductive dressing proved to be at least as safe as the standard of care (thin film) 
in dressing the DSW, with only a quarter of patients reporting an adverse event in the the 
hydroconductive dressing group compared to more than two thirds of patients in the thin 
film group (P=0.003).  Notably, when adverse events were present in the hydroconductive 
dressing group, they were also present in the thin film group.   
 
Our study is not without limitations. A full cost analyses based on the number of dressing 
changes and length of hospital stay would further substantiate the use of this locally 
manufactured dressing. Also, we did not address how the added paraffin gauze could 
influence the wound healing parameters. Nevertheless, this addition was essential as the test 
dressing could adhere to the raw wound surface and remove early epithelialization with 
subsequent dressing changes. 
 
The level of evidence from our study, in addition to the research methodology being a 
prospective and within-patient controlled design, suggests that we can at least review that 
the standard of care dressing in treating DSWs in our setting be replaced with the locally 
manufactured dressing Drawtex®. A larger, prospective, multi-center trial could yield even 
more convincing evidence to suggest a change in practice.    
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CHAPTER 5 
CONCLUSION 
Our study shows that the hydroconductive dressing with Levafibre technology in treating 
DSWs has significantly quicker rates of epithelialisation by Day-5 post-operatively 
compared to the current standard dressing of care.  Moreover, patients experienced the the 
hydroconductive dressing wounds to be significantly less painful throughout the healing 
period when compared to the standard dressing of care. Importantly, the hydroconductive 
dressing matches the safety profile of the standard of care dressing, with a lower frequency 
of adverse events noted, when compared to thin film. Finally, the hydroconductive dressing 
treated group reported no incidences of infection or conversion to full thickness wounds.  
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Introduction / background 
Split-thickness skin graft donor sites are partial-thickness wounds that heal by the 
process of epithelialization.  These wounds are painful and run the risk of infection, 
conversion to full-thickness wounds, and scar hypertrophy.  Many therapies have 
been introduced for the treatment of these donor site wounds.  The ideal dressing 
should be one that maintains a moist pH-balanced wound, maintains exudates, 
limits infections, minimizes disturbance of healing tissue beneath the dressing, 
reduces pain to the patient, and limits the number of dressing changes. The 
standard practice for donor site wounds depends on the depth of the wound and the 
co-morbidities that the patient possesses. At our institution the current standard of 
care is the use of Opsite (transparent film – adherent to wound surface) covered 
with a bulky gauze dressing.  The frequency with which the dressings are changed 
is arbitrary and dictated by the volume of drainage or the physical condition of the 
dressing. Drawtex, a  low adhernet Hydroconductive dressing, utilizes Levafibre 
technology. Levafibre Technology is a combination of two types of cross- action 
structures that create the ability to move exudate from the wound bed through the 
dressing. Drawtex can decrease bacteria and deleterious cytokines from the wound. 
This reduces the risk of infection and maceration of the wound.  
 
Dressings and management of Split thickness skin graft donor sites, have been 
studied with inconclusive results and lack of consensus.  A wide variety of 
dressings, ranging from simple dressings for example Polyurethane film, to more 
complex dressings like silver (Acticoat®)[1]-, or growth-factor impregnated 
dressings (rh-aFGF)[2] have been studied in the management of donor sites (for 
split thickness skin grafting) . In smaller comparative studies, some of these 
dressings proved to be superior in acceptability, ease of use and efficacy, like 
Veloderm, compared to Algisite M® and Jaloskin® in 2006 [3].  Even mildly 
absorptive materials, like Xeroform® have been compared for instance to Jellonet®, 
but showed no benefit even in terms of cost effectiveness[4].  In 2009 bigger studies 
where a 100 patients were dressed with a range of dressings including Aquacel 
Ag®, Bactigras®, Comfeel® snd Opsite®, none of the tested materials were found 
to be ideal, but made some recommendations as to which dressings caused less 
pain than others [5].  One of the only prospective, randomised control studies from 
the Journal of Burn Care in 2011, a pilot study, again showed no significant 
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difference between materials tested with regards to healing time, infection rates and 
cosmetic outcome[6].  Bovine collagen in a comparison cohort study proved to 
achieve greater epithelialisation and less pain with dressing changes compared to a 
polyurethane film & Rayon® soaked in 0,9% Saline[7], An ionic silver-containing 
dressing also proved superior to paraffin gauze with regards to pain and time to 
complete epithelialisation[8].  
In an article (1998, Journal for applied nursing res) integrating the available 
empirical evidence regarding STSG donor site dressings, a review of 33 studies 
was published: Transparent film was found to be the best dressing care with the 
fastest healing rates, a smooth reepithelialised surface and a low infection rate, with 
the least amount of pain and at minimal cost[9].  This is the standard of care for 
today.  It is known however, that disadvantages to the polyurethane dressing were 
post operative leakage from under the dressing on the donor site, and fragility of 
this newly healed donor site[10] 
The previously mentioned silver containing hydrofiber dressing in [8] (compared to 
paraffin gauze) was also found to be superior in guarding against secondary 
infection[11], but these dressings are expensive and not readily available in state 
sector. 
A relatively cheap, non complex dressing, readily available in state sector, 
manufactured by a South African company have not yet been compared (in 
convincing studies with convincing research methodology) to the standard of care - 
polyurethane film, or Opsite®.    
 
Taking this background into account, the following question arises: 
 Is there a better way of managing split thickness skin graft donor sites; using 
Drawtex (a hydroconductive dressing) compared to the current standard of care, in 
order to achieve quicker healing time, better quality of healing and less pain and 
chance of infection overall? 
 
Aim & Objectives 
In this prospective -internally controlled study- we aim to investigate the efficacy of 
low adherent Drawtex (a hydroconductive dressing) in the healing of Split thickness 
donor sites compared to Opsite®, the standard dressing of care.  
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Specifically, the primary objectives of the study are: 
1. To compare the length of time to complete healing (>90% epithelialization) 
2.  To determine the quality of healing when the dressing separates and at 
three months after, based on the presence, or not, of scar hypertrophy, 
pruritis, erythema and induration. 
 
The secondary objectives of the study are: 
To measure the patient’s pain experience using the VAS(pain) scores at 24 
and 48 hours after application, and at 7 days 
To determine and compare the safety of low adherent Drawtex using the 
following parameters: 
 Presence of Infection  
 Conversion of donor site to full-thickness wound  
 
Hypothesis 
Drawtex improves the quality of healing and reduces the time to complete healing, 
pain experienced and the likelihood of infection in the post-operative period when 
compared to the current standard of care.   
 
Methods: 
This is a study comparison of 2 wound dressings for treatment of adult split-
thickness skin graft donor site wounds. 
 
Study Design 
This is a randomized, prospective, internally controlled study 
After obtaining the split-thickness skin grafts at the size and depth stated in the 
inclusion criteria, initial hemostasis will be achieved with pressure. Each of the 
wounds (paired) in the same patient will be randomized to receive either low 
adherent Drawtex (over and above a single layer of paraffin gauze covering the 
wound suface) or Opsite immediately adjacent to the wound surface.  The amount 
of skin harvested, will not exceed the amount needed to cover the defect.  Drawtex 
can then be added to the Drawtex donor site as a cover dressing and held in place 
with a wrap of the surgeon’s discretion. Standard burn gauze can be used as a 
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cover dressing to the Opsite treated donor site.  The outer wrap and outer layer of 
dressings can be replaced as needed, but the low adherent Drawtex or Opsite layer 
will remain in place.  If the inner layer of non-adherent Drawtex or Opsite must be 
removed and replaced,  it will be necessary to note that on the research record. 
Post operative day five, day ten and day fifteen (or day of discharge), photographs 
of the donor sites will be taken denoting the time to healing (90% epithelialisation); If 
the patient becomes an outpatient, he or she will return to the outpatient clinic to be 
reassessed for wound healing.  The clinician may on any moment decide to remove 
the covering wound dressing should he feel that it is surgically indicated to do so. It 
will be noted as an adverse event.  
 
Study Population 
Adult patients (18-60 years) presenting to the Trauma Unit at Charlotte Maxeke 
Johannesburg Academic Hospital and Leratong Hospital, that are predetermined to 
require a split-thickness skin graft with a resultant donor site wound and meet all 
study criteria will be enrolled in the study 
 
Sample Size 
The sample size will be approximately 20 patients. A review of literature has 
revealed an inadequate amount of existing research to determine a statistically 
powered sample size for this study. Therefore, Sample size selection was based on 
the feasibility of completing a small number of subjects in a pilot study to be used in 
the development of a larger study including sample size determination with power 
analysis.   
 
Inclusion Criteria 
 Patients with 2 non-contiguous donor site wounds from the harvesting of 
split-thickness skin grafts.  
 Donor site wound sizes of 50-250 cm2. The total area of donor sites created 
will not exceed the size of defect that needs to be covered.  
  Donor site depth 0.23 mm to 0.30 mm (0.010-0.012 inches).  Both donor 
sites on a single patient will be harvested to the same depth. 
 Both genders with an age 18-60 years at randomization 
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 Signed informed consent 
 Exclusion Criteria 
 Donor sites located on Head, neck , or hands  
 Patients with necrotising leucocytic vasculitis or pyoderma gangrenosa. 
 Diagnosed underlying disease(s) (e.g. HIV/AIDS or cancer) known to 
interfere with the treatment. 
 Patients with insulin dependent diabetes mellitus 
 Patients treated with systemic glucocorticosteroids, except patients taking 
occasional doses or doses less than 10mg prednisolon/day or equivalent. 
 Use of immunosuppressive agents, radiation or chemotherapy within the 
past 30 days. 
 Known allergy/hypersensitivity to any of the components of the 
investigation products. 
 Patients with physical and/or mental conditions that are not expected to 
comply with the investigation. 
 Participation in other clinical investigation(s) within 1 month prior to and at 
the start of the investigation. 
 Pregnancy 
Randomization  
Allocation of treatment of wounds sites will be done at random, using a pre-
determined random assignment of treatments to the 2 defined wound regions. 
Randomization scheme will be achieved using a computer-generated list (MS 
Excel). Wound regions will initially be labeled A and B by the physician, and then an 
envelope will be opened which will indicate which treatment to assign to A and 
which to B. One wound will be randomly assigned non-adherent Drawtex and the 
other wound will be assigned the Opsite standard of care dressing. 
The same Practitioner will attempt to change the dressings; however, it may not be 
possible for all cases. All dressing changes or reinforcements will be recorded in the 
research record. Wound assessments will occur until full epithelization (at least 90% 
closed and no longer in need of a dressing. If the patient becomes an outpatient, he 
or she will return to the outpatient clinic to be reassessed for wound healing. 
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Outpatient visits will occur as required per standard of care.  Study participation will 
not require more frequent visits to the outpatient clinic.  The wound dressing 
changes and treatments provided at the outpatient clinic will be standard of care. A 
final evaluation of wound healing and scarring of each donor site will be made at 
three months. 
 
Standard Surgical Practice 
All patients will receive the standard pain management and wound preparation 
methods.  
 The tangential harvesting and splitting of donor skin: 
 DAVIES GOLD SERIES DERMATOME, Duplex GD 103 
 ZIMMER, Meshgraft II Tissue expansion system 
Pain Management 
The standard pain management regimen at this institution is:  
 Paracetamol 1g QID PO 
 Tramadol 100 mg BD PO/IV/IM if needed 
Study Duration 
 
Data Recording 
Data will be collected at baseline, 24 hours after application of study dressings, and 
48 hours after application of study dressings, at 7 days, and at the time of complete 
wound epithelialization.  Final data will be collected at 3 months. Please see 
attached data collection sheet 
Statistical analysis: 
 2013 
 JAN FEB MRC APR MAY JUN JUL AUG 
Literature review         
Preparing protocol         
Protocol assessment         
Ethics application         
Collecting data         
Data analysis         
Writing up thesis         
Submission         
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Analysis Plan 
Data would be recorded in Excel and statistical comparisons made using 
STATISTICA, using non parametric tests. Univariate analyses will be used for 
distribution (ranges of values, frequency distribution), central tendency (mean, 
median, mode), and dispersion (range, standard deviation). If there are enough data 
to draw a conclusion, we will proceed with inferential statistics and stratification of 
groups according to age. Categorical data will be analysed using the Chi square 
test with Fisher correction for small numbers. 
 
Benefits and risks 
There is always the risk of one or more side effects developing in the course of 
treatment. For example, there may be a local irritation or even an allergic reaction to 
the treatment or the wound dressing. If this occurs, treatment with the non-adherent 
Drawtex dressing or Opsite will be discontinued. 
The study staff will be looking for any such adverse side effects during the entire 
course of the study.  
Another complication can be wound infection. If this occurs, the patient will be 
treated with an antibiotic. Pain is a common adverse effect of split-thickness skin 
graft donor sites and will be monitored. Conversion of the donor site to a full-
thickness wound can occur in any donor site and if such an event happens, the 
wound will be treated as seen fit by the surgeon. There may be risks or side effects 
which are unknown at this time.  The PI will perform a daily data review of any 
serious adverse events and conversions to full thickness.   
 
 Adverse Events 
Definition of Adverse Events (AE) 
Adverse events can be classified as either serious or non-serious. A serious 
adverse event is an occurrence of any of the following:   
 Death 
 Is life threatening  
 Requires prolongation of hospitalization time 
 Results in persistent or significant disability or incapacity 
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Common less serious adverse Events for Split-thickness Skin Graft Donor 
Sites 
Low grade fever, wound pain, itching, inflammation, anxiety, agitation and disruption 
of dressing  
Record All Adverse Events 
 All adverse events that occur after the initial dressing application will 
be considered treatment emergent adverse events. 
 Information on all AE’s should be recorded on the source document 
 At each contact with the subject the investigator must seek information 
on AEs by specific questioning, and as appropriate, by examination.  
 Serious Adverse Events that are still ongoing at the end of the study 
must be followed to determine the final outcome. 
The wound assessment for clinical evidence of infection is a study outcome and will 
be reported on the data collection form. It will not be considered an adverse event. 
Benefits to Patients 
We do not know if participation in this study will benefit the patient, however a 
favorable outcome as stated in the hypothesis, might decrease time to complete 
healing, decrease pain and decrease chances of infection, an overall decrease in 
length of stay in hospital. 
Costs 
The cost of a dermatome and mesher as described in ‘Standard Surgical practice’ 
have been undertaken by Beier Drawtex Healthcare, whom will also supply the  
Hydroconductive dressing material as described in the study design.  The material 
used for the compared donor site, is the ‘standard of care’, as would be the case if 
the patient was not enrolled in the study, needing a split thickness skin graft for 
whichever reason.  There are no financial conflicts of interest. 
Ethical considerations and informed consent 
In January 2013 , an application to the Human research ethics committee of 
Johannesburg was made to gain approval to conduct the study in the said hospitals.  
On 25 January 2013 approval was granted (M130105) subject to a small change, 
ensuring that donor sites won’t exceed the surface area needed to cover the original 
defect.  This change was incorporated in the study design and informed consent 
documents.  
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Consent process: 
Adult patients that are admitted to the surgical service who require a split-thickness 
skin graft will be screened for study eligibility on a daily basis. Any patient that 
meets the study eligibility will be approached by one of the research team members. 
If a patient is eligible for enrollment, the study will be explained to the subject. All 
study discussion will be conducted privately. The study design (aims, methods, 
benefits and risks) will be discussed and the consent will be reviewed.  The subjects 
will be informed that participation in the study is voluntary and that they may 
withdraw at any time; choosing against participation will not affect the care received 
for treatment. A copy of the consent will be left with the subject for review. A 
member of the research team will be available to answer any questions about the 
study. The research team will make case by case judgments on obtaining consent 
from the subject based upon their understanding of the research. If the study 
members feel that the individual providing consent does not understand the 
research, the patient will not be enrolled. The consenting research member will sign 
the ICF and a copy will be provided to the subject. Documentation of this process 
will be written in the patient’s medical record with a copy of the signed informed 
consent.  The subjects will be informed that they will be authorizing access of 
investigational staff to confidential medical records.  
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APPENDIX 2: Datasheet  
STUDY NUMBER    
PT NAME:                                                    
PATIENT ID NO :                                                  
DOA :                                                                            
PT FILE NO:                                                                                                                                             
      
 
PARTICIPATION NUMBER    
   
   
 
GENDER Male  Female 
 
 
       AGE   
      
   
        PRINCIPAL 
INVESTIGATOR Dr Barend Van Den Bergh 
  
RANDOMIZATION 
           SPONSOR Beier Drawtex Healthcare   WOUND  A   
   
   
  WOUND B   
INVESTIGATORS Dr Barend Van Den Bergh    
  
   Sandra Oosthuizen 
   
  INSTITUTION      
  
      
   
  
 
DATA COLLECTION 
   
   
 
 
 
  
 
Wound  
A Adverse events Wound  B Adverse events 
   24 Hours         
   
     
    
   48 Hours         
   
 
        
   7 Days         
   
 
        
   
     
 
 
 
   
 
  
 
  
    
WOUND LOCATION 
         
   
        
       
 
   
       
   
 
       
   
       
           
  
 
          
     
             
HOSPITAL 
STICKER 
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WOUND ASSESSMENT 
 
            Day 
5   
Signs of infection Surrounding Erythema Induration Pruritis Scar Hypertrophy 
 
Wound A Absent  Present Absent  Present Absent  Present Absent  Present Absent  Present 
 
  
 
Wound B Absent  Present Absent  Present Absent  Present Absent  Present Absent  Present 
Day 
10   
Signs of infection Surrounding Erythema Induration Pruritis Scar Hypertrophy 
 
Wound A Absent  Present Absent  Present Absent  Present Absent  Present Absent  Present 
 
  
 
Wound B Absent  Present Absent  Present Absent  Present Absent  Present Absent  Present 
Day 
15   
Signs of infection Surrounding Erythema Induration Pruritis Scar Hypertrophy 
 
Wound A Absent  Present Absent  Present Absent  Present Absent  Present Absent  Present 
 
  
 
Wound B Absent  Present Absent  Present Absent  Present Absent  Present Absent  Present 
3 
Mon
ths   
Signs of infection Surrounding Erythema Induration Pruritis Scar Hypertrophy 
 
Wound A Absent  Present Absent  Present Absent  Present Absent  Present Absent  Present 
 
  
 
Wound B Absent  Present Absent  Present Absent  Present Absent  Present Absent  Present 
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APPENDIX 3: Patient Participation and Informed Consent 
 
Introduction 
 
Good day my name is Dr Barend Van Den Bergh, I am a surgical registrar, in the Department of 
Surgery, Wits University and would like to invite you to consider participating in a research 
study, entitled - A Prospective, Internally controlled study to compare the ablility of a low 
adherent Drawtex Hydroconductive Dressing vs Opsite (Standard of care) on the healing of 
split thickness Skin graft donor sites. 
 
1. Before agreeing to participate in the study, it is important that you read and 
understand the following explanation of the purpose of the study, the study 
procedures, benefits, risks, discomforts and precautions as well the alternative 
procedures that are available to you, and your right to withdraw from the study at any 
time. This information leaflet is to help you decide if you would like to participate. You 
need to understand what is involved before you agree to take part in this study. 
2. If you have any questions please do not hesitate to ask me. 
3. You should not participate in the study unless you are satisfied about all the 
procedures involved. 
4. You may not participate in another investigational medicine research study, nor take 
any other investigational medicine while participating in this study. 
5. You should not have participated in an investigational study in the past 30 days 
6. Please be open with me regarding your health history, since you may otherwise harm 
yourself by participating in the study. 
7. If you decide to participate in this study you will be required to sign this document to 
confirm that you understand the study. You will be given a copy to keep. 
8. If you have a personal Doctor you need to inform him of the possible participation in 
the study. I can also notify the Doctor in this regard.  
 
PURPOSE OF THE STUDY: 
 The surgery you are scheduled for is a split thickness skin graft. You have been injured and 
we need to place new skin onto the wound site. We do this by taking uninjured skin from 
another part of your body – called the donor site - and placing it onto the wounded area. 
We would take skin from two donor sites of the same size/ The one donor site we would 
cover with the usual dressing or bandage (standard of care Opsite) and the other site we 
would cover with the new dressing (Hydroconductive Dressing). This is a new dressing 
which has recently become available in the Hospitals. 
 We will not take more skin, than what is needed to cover the area that needs skin replaced. 
 We would compare the healing time, the amount of pain you experience, and the 
appearance (quality) of the two sites to determine whether healing is better using the new 
bandage; with photographs of the wounds, which makes it scientifically comparable.   
 We would record personal data from your Hospital records (gender, reason and extent of 
injury, etc.) and follow up on the wound healing process. 
 
 LENGTH OF THE STUDY AND NUMBER OF PARTICIPANTS 
 20 participants will participate in this study. 
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 The participants will be between the ages 18 and 60 
 The total amount of time required for your participation in this study will be a maximum of 
3 months 
 You will seen by myself and my team, 7 times during the study. 
 
 
PROCEDURES 
 If you agree to take part in this study, you will first be asked questions and examined to see 
if you qualify for this study. 
 At each following visit you will undergo: 
o Visit 1 – 24 hours after the surgery - tell us how much pain you have. 
o Visit 2 – 48 hours after - tell us how much pain you have. 
o Visit 3 – 5 days after- we will expose your donor sites, examine and photograph 
the wounds and ask you a few questions. 
o Visit 4 – 7 days after - tell us how much pain you have. 
o Visit 5 – 10 days after- we will expose your donor sites, to examine and 
photograph the wounds and ask you a few questions 
o Visit 6 – 15 days after- we will expose your donor sites, to examine and 
photograph the wounds and ask you a few questions 
o Visit 7 – 3 months after- we will examine and photograph the donor sites and 
ask you a few questions 
 
WILL ANY OF THESE PROCEDURES RESULT IN DISCOMFORT?  
 There is pain associated with all surgical procedures, you would receive the standard pain 
management regime of the institution which is Parcetamol 1gr 4 times per day PO, OR 
Tramadol 100mg bd po/ivi/imi if need be. 
 Local irritation or even allergic reaction may occur, however the dressing has under gone 
trials and studies to prove biocompatibility and no know reactions have been reported. In 
the event of any of these symptoms occurring the dressings will be removed immediately 
and the use thereof discontinued. 
 Wound infection may occur. If this occurs you will be treated with an antibiotic. 
 Conversion to a full thickness wound may also occur, this will be managed by standard 
surgical procedures. 
 
RISKS OF THE STUDY DRESSING 
 No previous studies have been done on donor sites using Drawtex Hydroconductive 
dressings. 
 
UNFORSEEN RISKS 
 The study dressing is investigational and there may be other risks or side effects which are 
unforeseen or unknown. You should immediately contact me if any side effects occur 
throughout your participation in this study. 
 
BENEFITS 
 The potential benefit from your participation in this study may be that you would 
experience less pain and that your wounds would heal quicker, with no occurrence of 
infection. 
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 However, you may not benefit from this study. 
 Your participation in this study will contribute to medical knowledge that may help other 
patients that, like you, may need skin grafts with donor sites. 
 
ALTERNATIVE TREATMENT  
 Alternative treatment:  Opsite dressing of the wound, with a bulky gauze dressing over 
that, and this is the usual and standard of care for your wound. 
 If you decide not to take part in this study you will still receive the best current care, 
from your usual doctor; this may or may not include the study dressing. 
 
ARE THERE ANY WARNINGS OR RESTRICTIONS CONCERNING MY PARTICIPATION IN 
THIS STUDY? 
 If you are pregnant, you may not take part in the study. 
 You need to be between the age of 18-60. 
 If you suffer from insulin dependent diabetes you may not take part in the study. 
 If the doctor has diagnosed you with the following conditions you will not be able to be 
part of the study. Leucocytic Vasculitis or Pyoderma Gangrenosa. 
 If you are taking any medicine like glycocorticosteriods, doctor will explain what these 
are. 
 If you are using any immunosuppressant agents or have used in the last 30 days. 
 If you have had cancer and have had any treatment like chemo or radiation therapy, in 
the last 30 days. 
 If you are allergic to cotton, polyester, viscose you will not be able to take part in the 
study. 
 
INTERACTIONS 
 There are no known reactions and interactions to the study material. 
RIGHTS AS A PARTICIPANT IN THIS STUDY 
 Your participation in this study is entirely voluntary and you can decline to participate, or 
stop at any time, without stating any reason.  Your withdrawal will not affect your access to 
other medical care.  
 Discontinuation of study treatment.  
You must inform me if you wish to stop the study dressing 
WITHDRAWAL 
 Your withdrawal will not affect your access to other medical care.  
 I retain the right to withdraw you from the study if it is considered to be in your best 
interest. If your participation is ended early, you may be asked to return for study-
ending tests and procedures for your safety.  
 If you did not give an accurate history or did not follow the guidelines of the study and 
the regulations of the study facility, you may be withdrawn from the study at any time.  
 Pregnancy: Because the safety during pregnancy of the dressing used in this study 
has not been established, you will be withdrawn from the study, should you 
become pregnant during your participation. All aspects of healthcare related to 
your pregnancy and infant will be your responsibility.  
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 Dr Barend Van Den Bergh will require access to your medical records and those of 
your child, from the time you became pregnant and for a minimum of 12 weeks 
after the baby is born. 
EMERGENCY CARE AND HOSPITALIZATION 
 If you seek emergency care or if hospitalisation (with regards to the donor site) is 
necessary from the date of enrolment of the trial and for the 3 months to completion of 
the trial, please tell the treating doctor that you are enrolled in this research study and 
I must be informed. 
 
FINANCIAL ARRANGEMENTS 
Maisha Medical has provided payment for  
 Dressings 
 Transport to and from place of residence at AA rates. 
 Neither you nor your medical scheme will be expected to pay for any study dressings, 
study related visit or study procedures.   
 
 
ETHICAL APPROVAL: 
 This clinical study protocol has been submitted to the University of the Witwatersrand, 
Human Research Ethics Committee (HREC) and written approval has been granted by 
that committee.  
 The study has been structured in accordance with the Declaration of Helsinki (last 
updated: October 2008), which deals with the recommendations guiding doctors in 
biomedical research involving human participants.  A copy may be obtained from me 
should you wish to review it.  
 This study has been sponsored by Maisha Medical as indicated above. 
 
I and the doctors treating you do not have any financial or personal interests with this 
organisation that may bias my actions. 
 
ADDITIONAL INFORMATION 
For the duration of the study, you will be under the care of Dr Barend Van Den Bergh If at any 
time between your visits, you feel that any of your symptoms are causing you any problems, or 
you have any questions during the study, please do not hesitate to contact me. 
Other doctors from this department who are working on this study are: 
 PROF J GOOSEN 
 DR JONATHAN KOURIE 
 
The 24-hour telephone number through which you can reach me or another authorised 
person, is 083 468 9962  
 
 Please be aware that you need to follow all instructions given my myself or other doctors 
relating to your care at the Hospital and return for the follow-up visits. 
 
CONFIDENTIALITY 
 All information obtained during the course of this study, including hospital records, 
personal data and research data will be kept strictly confidential. Personal details would 
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recorded for the purpose of follow-up but such information would be kept separate from 
medical information by using a study number.  
 Data that may be reported in scientific journals will not include any information that 
identifies you as a participant in this study. 
 The final information would be reviewed by authorised representatives of Maisha 
Medical. 
 The information might also be inspected by the University of the Witwatersrand, Human 
Research Ethics Committee (HREC), and any other approved authorities. 
 These records will be utilised by such authorities only in connection with carrying out their 
obligations relating to this clinical study. 
 Any information uncovered regarding your test results or state of health as a result of your 
participation in this study will be held in strict confidence.  You will be informed of any 
finding of importance to your health or continued participation in this study but this 
information will not be disclosed to any third party in addition to the ones mentioned 
above without your written permission.  The only exception to this rule will be cases of 
communicable diseases where a legal duty of notification of the Department of Health 
exists.  In this case, you will be informed of my intent to disclose such information to the 
authorised state agency. 
 
 
DO YOU HAVE ANY QUESTIONS REGARDING THE STUDY? 
Yes/ No 
1. 
2. 
3. 
4. 
5. 
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INFORMED CONSENT: 
 I hereby confirm that I have been informed by the study doctor Dr Barend Van Den 
Bergh / Dr J Kourie about the nature, conduct, benefits and risks of clinical study:  
o Protocol Number: 
o Study Title: 
 I have also received, read and understood the above written information (Participant 
Information Leaflet and Informed Consent) regarding the clinical study. 
 I am aware that the results of the study, including personal details regarding my sex, 
age, date of birth, initials and diagnosis will be anonymously processed into a study 
report. 
 In view of the requirements of research, I agree that the data collected during this 
study can be processed in a computerised system by Maisha Medical or on their 
behalf.  
 I may, at any stage, without prejudice, withdraw my consent and participation in the 
study. 
 I have had sufficient opportunity to ask questions and (of my own free will) declare 
myself prepared to participate in the study.  
  
1. PARTICIPANT: 
 
Printed Name   Signature / Mark or Thumbprint                         Date 
 
 
2. STUDY DOCTOR 
I, Dr Barend Van Den Bergh herewith confirm that the above participant has been fully 
informed about the nature, conduct and risks of the above study. 
 
Printed Name   Signature   Date and Time 
 
 
3.TRANSLATOR OR ANY OTHER PERSON EXPLAINING THE CONSENT 
Designation: 
 
Printed Name    Signature   Date           
4. WITNESS  
 
 
Printed Name    Signature   Date 
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APPENDIX 4: Ethics Clearance Certificate 
 
